Multi-target Natural and Nature-Inspired Compounds against Neurodegeneration: A Focus on Dual Cholinesterase and Phosphodiesterase Inhibitors

Alzheimer’s disease is a memory-related neurodegenerative condition leading to cognitive impairment. Cholinergic deficit, together with other underlying mechanisms, leads the to onset and progression of the disease. Consequently, acetylcholinesterase inhibitors are used for the symptomatic treatment of dementia, even if limited efficacy is observed. More recently, some specific phosphodiesterase isoforms emerged as promising, alternative targets for developing inhibitors to contrast neurodegeneration. Phosphodiesterase isoforms 4, 5 and 9 were found to be expressed in brain regions that are relevant for cognition. Given the complex nature of Alzheimer’s disease and the combination of involved biochemical mechanisms, the development of polypharmacological agents acting on more than one pathway is desirable. This review provides an overview of recent reports focused on natural and Nature-inspired small molecules, or plant extracts, acting as dual cholinesterase and phosphodiesterase inhibitors. In the context of the multi-target directed ligand approach, such molecules would pave the way for the development of novel agents against neurodegeneration. More precisely, according to the literature data, xanthines, other alkaloids, flavonoids, coumarins and polyphenolic acids represent promising scaffolds for future optimization.

[1]  A. Blokland,et al.  Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation , 2004, Psychopharmacology.

[2]  O. Sanders,et al.  Phosphodiesterase Inhibitors for Alzheimer’s Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale , 2020, Journal of Alzheimer's disease reports.

[3]  Haibin Luo,et al.  Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids. , 2019, Bioorganic & medicinal chemistry letters.

[4]  Lynn A. Hyde,et al.  The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents , 2011, Neuropharmacology.

[5]  J. Lanciego,et al.  Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD , 2013, Neuropharmacology.

[6]  Manjinder Singh,et al.  Flavones: an important scaffold for medicinal chemistry. , 2014, European journal of medicinal chemistry.

[7]  H. Kinney,et al.  Caffeine improves the ability of serotonin-deficient (Pet-1−/−) mice to survive episodic asphyxia , 2013, Pediatric Research.

[8]  Jian Li,et al.  Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease. , 2017, ACS chemical neuroscience.

[9]  K. Reymann,et al.  The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents , 2008, Neuropharmacology.

[10]  B. Oyinloye,et al.  In vitro antioxidant and enzyme inhibitory properties of the n-butanol fraction of Senna podocarpa (Guill. and Perr.) leaf , 2019, Journal of basic and clinical physiology and pharmacology.

[11]  Jing Liu,et al.  Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease. , 2018, European journal of medicinal chemistry.

[12]  Dong I. Lee,et al.  Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span , 2018, Neurobiology of Aging.

[13]  G. Ribaudo,et al.  New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is). , 2016, Current medicinal chemistry.

[14]  K. Duodu,et al.  Phenolic Composition and Bioactive Properties of Cell Wall Preparations and Whole Grains of Selected Cereals and Legumes , 2014 .

[15]  J. Klimeš,et al.  Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine , 2014, Expert opinion on drug safety.

[16]  G. Oboh,et al.  Comparative Effects of Alkaloid Extracts from Aframomum melegueta (Alligator Pepper) and Aframomum danielli (Bastered Melegueta) on Enzymes Relevant to Erectile Dysfunction , 2017, Journal of dietary supplements.

[17]  Hui Qi,et al.  Dose–response meta‐analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease , 2014, Geriatrics & gerontology international.

[18]  G. Oboh,et al.  Modulation of some markers of erectile dysfunction and malonaldehyde levels in isolated rat penile tissue with unripe and ripe plantain peels: identification of the constituents of the plants using HPLC , 2017, Pharmaceutical biology.

[19]  S. Patra,et al.  Development of Xanthine Based Inhibitors Targeting Phosphodiesterase 9A , 2017 .

[20]  Xinhai Zhu,et al.  Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor , 2015, Molecular Pharmacology.

[21]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[22]  H. Rosenbrock,et al.  Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP , 2012, Neuropharmacology.

[23]  V. Lemos,et al.  The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue. , 2009, European journal of pharmacology.

[24]  M. Memo,et al.  Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach , 2019, Natural product research.

[25]  C. Lugnier,et al.  Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (+/-)-naringenin. , 2005, Planta medica.

[26]  F. Leonetti,et al.  Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds , 2018, Molecules.

[27]  G. Ribaudo,et al.  Isoflavones from Maclura pomifera: structural elucidation and in silico evaluation of their interaction with PDE5 , 2017, Natural product research.

[28]  Yuren Jiang,et al.  Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease. , 2017, Bioorganic & medicinal chemistry letters.

[29]  G. Ribaudo,et al.  Semi-synthetic isoflavones as BACE-1 inhibitors against Alzheimer's disease. , 2019, Bioorganic chemistry.

[30]  Sai-Sai Xie,et al.  Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease. , 2015, European journal of medicinal chemistry.

[31]  Wei Zhang,et al.  Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  G. Ribaudo,et al.  Semi-synthetic derivatives of natural isoflavones from Maclura pomifera as a novel class of PDE-5A inhibitors. , 2015, Fitoterapia.

[33]  G. Ribaudo,et al.  An Overview of New Possible Treatments of Alzheimer's Disease, Based on Natural Products and Semi-Synthetic Compounds. , 2017, Current medicinal chemistry.

[34]  Manjinder Singh,et al.  Hybrids: a new paradigm to treat Alzheimer’s disease , 2015, Molecular Diversity.

[35]  G. Ribaudo,et al.  The Medicinal Chemistry of Natural and Semisynthetic Compounds against Parkinson's and Huntington's Diseases. , 2017, ACS chemical neuroscience.

[36]  Hendrik van den Bussche,et al.  Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.

[37]  M. Díaz-Ríos,et al.  Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. , 2014, Life sciences.

[38]  A. Herman Caffeine’s Mechanisms of Action and Its Cosmetic Use , 2012, Skin Pharmacology and Physiology.

[39]  A. Kappo,et al.  Ocimum gratissimum Linn. Leaves reduce the key enzymes activities relevant to erectile dysfunction in isolated penile and testicular tissues of rats , 2019, BMC Complementary and Alternative Medicine.

[40]  G. Grześk,et al.  Role of acetylcholine and calcium ions in three vascular contraction models: Angiotensin II, phenylephrine and caffeine. , 2012, Experimental and therapeutic medicine.

[41]  G. Oboh,et al.  Extracts from Almond (Terminalia catappa) leaf and stem bark mitigate the activities of crucial enzymes and oxidative stress associated with hypertension in cyclosporine A-stressed rats. , 2020, Journal of food biochemistry.

[42]  R. Young,et al.  Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. , 2010, Bioorganic & medicinal chemistry letters.

[43]  T. Mohamed,et al.  Selective inhibition of human acetylcholinesterase by xanthine derivatives: in vitro inhibition and molecular modeling investigations. , 2013, Bioorganic & medicinal chemistry letters.

[44]  Huyuan Yang,et al.  What Is Already Known about This Subject What This Study Adds , 2022 .

[45]  M. Memo,et al.  Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist , 2020, ACS chemical neuroscience.

[46]  S. R. Salian,et al.  Design and Microwave Assisted Synthesis of Coumarin Derivatives as PDE Inhibitors , 2016, International journal of medicinal chemistry.

[47]  O. Forlenza,et al.  To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer’s disease , 2009, European Archives of Psychiatry and Clinical Neuroscience.

[48]  G. Ribaudo,et al.  Antioxidant Potential of Psychotropic Drugs: From Clinical Evidence to In Vitro and In Vivo Assessment and toward a New Challenge for in Silico Molecular Design , 2020, Antioxidants.

[49]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[50]  E. Karran,et al.  Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues , 2010, Neuropharmacology.

[51]  M. Memo,et al.  2-(3,4-Dihydroxyphenyl)-4-(2-(4-nitrophenyl)hydrazono)-4H-chromene-3,5,7-triol , 2020, Molbank.

[52]  G. Ribaudo,et al.  5-Hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one , 2018, Molbank.

[53]  Astrid Nehlig,et al.  Is caffeine a cognitive enhancer? , 2010, Journal of Alzheimer's disease : JAD.

[54]  M. Memo,et al.  A Perspective on Natural and Nature-Inspired Small Molecules Targeting Phosphodiesterase 9 (PDE9): Chances and Challenges against Neurodegeneration , 2021, Pharmaceuticals.

[55]  K. Gołembiowska,et al.  The Effect of Adenosine A2A Receptor Antagonists on Hydroxyl Radical, Dopamine, and Glutamate in the Striatum of Rats with Altered Function of VMAT2 , 2012, Neurotoxicity Research.

[56]  G. Oboh,et al.  Modulatory effect of quercetin and its glycosylated form on key enzymes and antioxidant status in rats penile tissue of paroxetine-induced erectile dysfunction. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[57]  M. Pohanka The perspective of caffeine and caffeine derived compounds in therapy. , 2015, Bratislavske lekarske listy.

[58]  N. Tsuno,et al.  Donepezil in the treatment of patients with Alzheimer’s disease , 2009, Expert review of neurotherapeutics.

[59]  Manjinder Singh,et al.  Exploration of multi-target potential of chromen-4-one based compounds in Alzheimer's disease: Design, synthesis and biological evaluations. , 2017, Bioorganic & medicinal chemistry.

[60]  T. Nicholas,et al.  A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. , 2014, Current Alzheimer research.

[61]  Laura Orian,et al.  Major Depressive Disorder and Oxidative Stress: In Silico Investigation of Fluoxetine Activity against ROS , 2019, Applied Sciences.

[62]  M. Pohanka Alzheimer´s disease and oxidative stress: a review. , 2013, Current medicinal chemistry.

[63]  Marine Peuchmaur,et al.  β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy. , 2021, Journal of medicinal chemistry.

[64]  G. Ribaudo,et al.  Psychiatric Disorders and Oxidative Injury: Antioxidant Effects of Zolpidem Therapy disclosed In Silico , 2019, Computational and structural biotechnology journal.

[65]  M. Memo,et al.  Combinatorial library generation, molecular docking and molecular dynamics simulations for enhancing the isoflavone scaffold in phosphodiesterase inhibition , 2020 .

[66]  T. Hartmann,et al.  Unique Role of Caffeine Compared to Other Methylxanthines (Theobromine, Theophylline, Pentoxifylline, Propentofylline) in Regulation of AD Relevant Genes in Neuroblastoma SH-SY5Y Wild Type Cells , 2020, International journal of molecular sciences.

[67]  Liang Shen,et al.  Berberine: A Potential Multipotent Natural Product to Combat Alzheimer’s Disease , 2011, Molecules.

[68]  C. J. Schmidt Phosphodiesterase inhibitors as potential cognition enhancing agents. , 2010, Current topics in medicinal chemistry.

[69]  A. O. Ademiluyi,et al.  Phenolic analysis and erectogenic function of African Walnut (Tetracarpidium conophorum) seeds: The impact of the seed shell on biological activity. , 2019, Journal of food biochemistry.

[70]  M. Štrucl,et al.  Cognitive and autonomic dysfunction in presymptomatic and early Huntington’s disease , 2014, Journal of Neurology.

[71]  N. K. Simas,et al.  Phytochemical and allelopathic studies of Terminalia catappa L. (Combretaceae) , 2012 .